A landmark study on GLP-1 side effects just surfaced symptoms that clinical trials may be missing.
A team at the University of Pennsylvania just did something that drug companies and the FDA have not: they listened to 70,000 people talking about their weight-loss drugs on Reddit—systematically, at scale, using AI—and found side effects that aren’t showing up in clinical trial data.
The study, published in Nature Health this week, analyzed more than 400,000 posts across GLP-1-related subreddits spanning over five years. The researchers used natural language processing to extract patient-reported symptoms from semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) users and compared them against known side effect profiles. (Penn Engineering)
The expected findings were there—nausea, gastrointestinal distress, the symptoms that made it into the prescribing information. But the unexpected findings are what make this paper worth reading.
Underreported GLP-1 Side Effects Found in Reddit Data
Two categories of symptoms appeared at rates the researchers flagged as significantly underrepresented in formal adverse event reporting:
Reproductive symptoms. Irregular menstrual cycles were reported frequently enough to clear statistical thresholds—a finding that has been circulating anecdotally in Reddit communities for over a year but hasn’t generated formal pharmacovigilance attention. The mechanism is biologically plausible: GLP-1 receptors are expressed in reproductive tissues, and rapid weight loss is independently associated with menstrual disruption. But “biologically plausible” is not “confirmed,” and that distinction matters.
Temperature dysregulation. Chills and hot flashes appeared as a cluster that doesn’t map neatly onto the known GI side effect profile. These symptoms could be related to metabolic rate changes, could be coincidental, or could represent a genuine pharmacological effect that trials weren’t designed to capture. The data raises the question. It doesn’t answer it.
Beyond those two categories, psychiatric symptoms—anxiety, insomnia, depression—showed up in roughly 13% of users reporting side effects. And fatigue was the second most commonly reported symptom overall, despite being underrepresented in trial reporting thresholds. (Medical News Today; Medscape)
What This Study Is—and Isn’t
This is a GLP-1 side effects signal detection study, not a causal analysis. The researchers are the first to say so: Reddit users who post about their medications are not a representative sample. They skew younger, more male, and more US-based than the general GLP-1 patient population. People who have side effects are more likely to post about them than people who don’t. And correlation in a Reddit dataset is several inferential steps away from “semaglutide causes irregular periods.”
What the study is good at: identifying blind spots. Clinical trials are designed to detect specific, predefined GLP-1 side effects and other adverse events. They’re less good at catching symptoms that patients describe in their own language, that don’t fit neatly into MedDRA coding categories, or that emerge only with longer real-world use. Reddit—messy, uncontrolled, self-selected Reddit—generates the kind of unstructured signal that formal pharmacovigilance systems are structurally bad at detecting.
The Penn team’s AI framework essentially builds a bridge between the two: take the unstructured patient language, extract the symptom clusters, and present them as hypotheses worth investigating in formal settings.
Why This Matters for the Peptide Space
GLP-1 agonists are the most commercially significant peptide class in history. Semaglutide and tirzepatide are generating tens of billions in annual revenue. They are also—because of that commercial scale—generating the largest naturalistic dataset of peptide side effects ever assembled, entirely by accident, on social media.
If Reddit can surface underreported GLP-1 side effects, the implication for tracking GLP-1 side effects—and side effects of less-studied peptides—is sobering. BPC-157, TB-500, GHK-Cu, and the other compounds in the gray-market peptide ecosystem don’t have 400,000 Reddit posts to mine. They don’t have Phase III trials. They don’t have formal adverse event reporting at all. The side effects that aren’t being detected for those compounds aren’t being detected because nobody is looking—not because they don’t exist.
The Penn study is, in a sense, a demonstration of what adequate pharmacovigilance looks like when you have enough data. For most peptides people are injecting themselves with, we don’t.
What Peptidings Is Doing
We’re reviewing our semaglutide and tirzepatide compound articles to determine whether the Safety sections should reference this study. Our standard is clear: we cite peer-reviewed findings, scope them precisely to their evidence base, and distinguish between “signal detected in observational data” and “confirmed causal relationship.” This study is the former—and the former is worth reporting honestly.
We’re also watching for the formal pharmacovigilance response. If the FDA or EMA initiates a signal assessment based on this data, that would be a significant escalation. We’ll cover it if it happens.
For the full evidence reviews including Safety profiles, see our compound articles on semaglutide, tirzepatide, and our Weight Loss and Metabolic Health research hub.
For the full evidence review on semaglutide or tirzepatide, including Safety, Dosing, and Claims vs. Evidence, see our Weight Loss and Metabolic Health research hub.
This is what happened. Want to know what it means?
The Peptidings newsletter delivers evidence-based analysis of peptide news—every Monday morning. No hype. No hedging. Just the Dutch Uncle's honest take.